ERBB2 and non-small cell lung carcinoma: Additionally, T-Dxd was the first ADC approved for use in patients with HER2-mutant non-small cell lung cancer (NSCLC) following the results of the DESTINY-Lung01 and DESTINY-Lung02 trials, reporting an ORR of 56% (95% confidence interval, 41.73–70.0) and a duration of response (DOR) of 16.8 months (95% confidence interval, 6.4-not estimable) [80,81].